PSMB3
ENSG00000277791
Target class
Enzyme
Chromosome
17
Approved drugs
3
Clinical candidates (approved and in development)
6
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- PSMB3
- Gene name
- Proteasome 20S subunit beta 3
- Gene symbol
- PSMB3
- Protein name
- Proteasome subunit beta type-3 (Proteasome chain 13) (Proteasome component C10-II) (Proteasome subunit beta-3) (beta-3) (Proteasome theta chain)
- HC10-II
- MGC4147
- Gene biotype
- Protein coding
- Gene family
- Proteasome
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 302.25
- Tissue specificity (Gini)
- 0.172
- Tissue specificity (tau)
- 0.575
- KEGG gene identifiers
- hsa:5691
- Protein interaction confidence
- 0.946313
- Protein interaction partners
- 64
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 43 more, listed on the interactive page.
- End position
- 38764231
- Start position
- 38752736
- Chromosome
- 17
- Strand
- Forward
- Cytoplasm . Nucleus . Note=Translocated from the cytoplasm into the nucleus following interaction with AKIRIN2, which bridges the proteasome with the nuclear import receptor IPO9. .
- PubMed 12181345
- PubMed 34711951
- Tissue specificity (tau)
- 0.575212
- Expression inequality (Gini)
- 0.172276
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 302.25
- Whole Blood
- 218.58
- Cells - Cultured fibroblasts
- 195.93
- Spleen
- 179.63
- Lung
- 178.19
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes302.25
- Whole Blood218.58
- Cells - Cultured fibroblasts195.93
- Spleen179.63
- Lung178.19
- Artery - Aorta170.73
- Adrenal Gland169.18
- Thyroid168.76
- Cervix - Endocervix163.48
- Artery - Coronary161.83
- Nerve - Tibial159.25
- Uterus159.08
- Artery - Tibial157.65
- Cervix - Ectocervix155.42
- Prostate151.35
- Fallopian Tube150.59
- Skin - Sun Exposed (Lower leg)149.68
- Bladder147.2
- Esophagus - Muscularis146.89
- Adipose - Subcutaneous146.68
- Breast - Mammary Tissue143.78
- Kidney - Medulla143.51
- Skin - Not Sun Exposed (Suprapubic)142.88
- Colon - Sigmoid142.44
- Vagina140.37
And 29 more, listed on the interactive page.
- GO:0006979
- GO:0010498
- GO:0043161
- GO:0061136
- GO:0000502
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0005839
- GO:0070062
- GO:0005515
- GO:0140756
Related records
Trials (799)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (6)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Marizomib 20S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor